Clinical research

Clinical research comprises scientific studies conducted to generate medical knowledge, answer scientific questions, identify more effective methods for preventing and treating diseases, and evaluate the safety, efficacy and side effects of new medicines, medical devices, diagnostic methods and treatment approaches before they enter routine practice. At Acıbadem University it is carried out in the two training and research hospitals, Atakent and Maslak, and across the Acıbadem Healthcare Group.

KlinikAr has operated since October 2019 to facilitate Phase II, III and IV clinical trials. It provides compliance with current Good Clinical Practice standards and the technical and operational support needed at every step, with a team of experienced professionals within the institution, and was established to increase the number of clinical trials within the Acıbadem Healthcare Group and to monitor processes legally and financially for researchers and hospital management. Its aim is an environment in which clinicians are less concerned with the aspects of a trial beyond the scientific protocol.

Members represent the Medical Directorate, the Dean of the School of Medicine, Planning and Business Development (pricing and contract management), Progress Payment and System Development, and the Legal Department. The board evaluates each drafted project operationally and financially, builds the business plan with interested parties, guides the preparations before and after Clinical Research Ethics Committee approval, supports contract and protocol correspondence, arranges logistics and human-resources support during the study, and meets four times a year for regular review. Contact: KlinikAr@acibadem.com.

Clinical research, medical-device investigations, stem-cell studies and observational studies with human medicinal products are evaluated by the Acıbadem Mehmet Ali Aydınlar University Clinical Research Ethics Committee (TİTCK code 2025-KAEK-51, approved 11 July 2025). Details, scope, calendar, forms and fees are on Ethics committees.

The seventh Sector Meeting of the Health Policy Center (April 2019) examined clinical research from public, private-sector and academic perspectives with the Rector Prof. Ahmet Şahin, the Dean of the School of Medicine Prof. Yasemin Alanay, Prof. A. Yağız Üresin (International Network of Clinical Research Centers), Gökhan Özkan (TİTCK Clinical Trials Department), Dr. Birol Tibet (TÜSEB Institute of Health Policies), Dr. Ümit Dereli (AIFD) and Dr. Hasan Ersin Zeytin (Pharmaceutical Manufacturers Association of Türkiye). The panel highlighted the expertise, multidisciplinary collaboration and long-term commitment that high-quality clinical studies require.

• The Phase 3 clinical trial led by Prof. Gül Başaran received full FDA approval following inspection.
• Prof. Javad Parvizi’s work at the International Joint Center set the international criteria for diagnosing periprosthetic joint infection and brought biomarker tests on joint fluid into clinical use.
• A urine-based HPV test and a rapid antibiotic susceptibility test developed by Prof. Tanıl Kocagöz and Prof. Özge Can with Bio-T at the Technology Development Center are entering clinical use.
• The TÜSEB–Acıbadem University cooperation agreement supports health research across the group’s hospitals.